BUZZ-Zealand Pharma tracks worst day ever as obesity drug trial results disappoint

Reuters03-06 16:17
BUZZ-Zealand Pharma tracks worst day ever as obesity drug trial results disappoint

** Shares in Zealand Pharma ZELA.CO tank 28%, on track for their worst day ever, after the Danish drugmaker and partner Roche's ROG.S experimental obesity drug's mid-stage trial results disappointed the market

** Jefferies says the weight loss of 10.7% at 42 weeks for petrelintide falls short of its 13-15% bar

** The data follows results for Eli Lilly's LLY.N amylin-mimicking drug candidate eloralintide, which helped patients lose as much as 20.1% of their weight after 48 weeks in a mid-stage study

** "It does not seem viable to push a best-in-class narrative at this stage," Jefferies says

** KBC echoes this by saying the outcome makes first-line positioning difficult; it views petrelintide as better suited for weight loss maintenance

** Roche shares are down 1.6% in early trading

** The Zealand Pharma stock is at the bottom of Europe's STOXX 600 index .STOXX, trading at its lowest levels since August 2023

(Reporting by Jagoda Darlak)

((Jagoda.Darlak@thomsonreuters.com; +48 58 769 65 40;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment